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Osteopontin expression in anglotensin Il-induced tubulointerstitial ne-
phrltls. Osteopontin is an arginine-glycine-aspartate (RGD) containing
secreted phosphoprotein recently shown to stimulate a local macro-
phage influx when injected subcutaneously in mice. We examined the
effect of angiotensin II infusion on renal injury and osteopontin expres-
sion in the rat kidney by in situ hybridization and immunohistochem-
istry. Preceding pathologic changes in tubular and interstitial cells, a
dramatic increase in renal osteopontin protein and mRNA levels was
observed primarily in epithelial cells of the distal tubules, collecting
ducts and Bowman's capsule. Although both cortex and medulla
showed increased osteopontin levels, the effect was most pronounced
in the renal cortex which normally showed very little constitutive
osteopontin expression. Interestingly, regions of the kidney expressing
high osteopontin levels correlated with sites of monocyte/macrophage
accumulation. These observations, coupled with recent findings that
osteopontin may be a pro-inflammatory protein, suggests that osteo-
pontin over-expression may facilitate monocyte/macrophage accumu-
lation at the sites of renal tubulointerstitial injury.
In many glomerular and extraglomerular renal diseases the
risk for progression to end-stage renal failure depends largely
on the severity of the injury to the tubulointerstitial compart-
ment [1, 2]. In several diseases associated with tubulointerstitial
injury, the degree of interstitial mononuclear cell infiltration
correlates both with the degree of renal dysfunction and the risk
for progression [reviewed in 3]. Understanding the pathogene-
sis of tubulointerstitial injury and fibrosis is therefore of para-
mount interest.
We have studied a model of angiotensin II (Ang 11)-mediated
hypertension in rats induced by continuous infusion of Ang II
by subcutaneous minipump [4]. In this model, a decrement in
renal function occurred and was associated with significant
phenotypic and proliferative changes in the various renal cell
populations. Most notably, focal tubulointerstitial injury with
tubular atrophy and dilation, cast formation, and interstitial
fibrosis with type IV collagen deposition developed. These
changes were associated with tubular and interstitial cell pro-
liferation, local PDGF B-chain mRNA expression, and an
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interstitial inflammatory infiltrate composed predominantly of
monocyte-macrophages.
A possible role for Ang II in mediating tubulointerstitial
injury is supported by the observation that tubulointerstitial
disease occurs in models of hypertension [5] and in a model of
ureteric obstruction associated with elevated renin [6]. Dia-
mond and Anderson have also reported that the tubulointersti-
tial injury that occurs in an experimental model of nephrotic
syndrome is prevented if angiotensin II generation is blocked by
angiotensin I converting enzyme inhibitors [7].
In this paper, we explore a potential mechanism by which
angiotensin II and/or hypertension may mediate the macro-
phage influx that occurs in tubulointerstitial disease. Specifi-
cally, a dramatic increase in the expression of osteopontin
mRNA and protein occurs focally in cortical renal tubules
during the course of angiotensin II infusion. The elevated
expression of osteopontin occurred early, and was followed
first by a monocyte/macrophage influx and subsequently, tubu-
lar damage. The observations that the macrophage localized
almost exclusively to sites of tubular osteopontin expression is
of interest because osteopontin has previously been shown to
bind with high affinity to murine macrophages and to induce a
macrophage rich cellular infiltrate upon in vivo inoculation in
mice [8]. This suggests that the tubulointerstitial damage that
accompanies Ang Il-induced hypertension may result from an
osteopontin-mediated monocyte/macrophage accumulation in
the interstitium.
Methods
Experimental protocol
The Ang II infusion protocol has been described previously
[4]. The kidney tissues obtained from that study (group 1; N =
12) in addition to a separate group of similarly treated rats
(group 2, N = 6) were used in these studies. Briefly, male
Sprague-Dawley rats (Zivic Miller, Allison Park, Pennsylvania,
USA) weighing 400 to 550 g (-—3 month old) received continuous
Ang II infusion (200 ng/min) via subcutaneous osmotic minip-
umps (Alzet model 2002, ALZA Corp., Palo Alto, California,
USA) containing Ang II (Sigma, Chemical Co., St. Louis,
Missouri, USA) dissolved in Ringer's lactate [4]. Control rats
had subcutaneous osmotic minipumps containing Ringer's lac-
tate only. Rats in group 1 underwent renal biopsy by flank
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incision under ether anesthesia at seven days and were sacri-
ficed at 14 days. Systolic arterial blood pressures were mea-
sured by tail cuff plethysmography in conscious, restrained rats
as previously described [9]. Blood pressures were normal
through day 3; in group I angiotensin lI-infused rats blood
pressures were 156 14 at 7 days and 172 7 mm Hg at 14
days; respective values in control rats were 124 15 and 138
21 mm Hg as previously reported [4]. Rats in group 2 (control
and Ang IT-infused, N = 6) were treated identically as those in
group 1 except that renal biopsies were obtained from three rats
in each treatment group four days following infusion, and the
remaining three were killed at day 7, and dissected kidney
cortexes and medullas were collected for fixation, RNA and
protein extract preparation. Blood pressures in group 2 at day 6
were 188 16 mm Hg in angiotensin IT-infused rats and 135
10 mm Hg in control rats.
Histology and immunohistochetnistry
Methyl Carnoy's-fixed tissues were embedded, processed,
and 4 m sections stained with the periodic acid/Schiff reagent
(PAS) with hematoxylin counterstain or with Gomori's tn-
chrome. Additional 4 j.m sections were immunostained using
an indirect avidin-biotin immunoperoxidase method [4] with
either a murine monoclonal antibody to rat osteopontin, MPI-
JIB 10(1) (obtained from the Developmental Studies Hybridoma
Bank maintained by the Department of Pharmacology and
Molecular Sciences, Johns Hopkins University School of Med-
icine, Baltimore, Maryland, and the Department of Biological
Sciences, University of Iowa, Iowa City, Iowa, USA under
contract NOl-HD-6-2915 from the NICFID), an affinity-purified
rabbit polyclonal antibody, 2arC, directed to recombinant
mouse osteopontin [10], or a specffic murine monoclonal anti-
body, ED-I (Bioproducts for Science, Indianapolis, Indiana,
USA), to monocyte, macrophage, and dendritic cells [11].
Double immunolabeling of the same tissue sections was per-
formed with the 2arC and ED-i antibodies in which the 2arC
was detected by a biotinylated goat anti-rabbit IgG (Vector),
and the ED-i was detected by immunogold with a gold-labeled
goat antimouse IgG (Amersham). Negative controls for the
immunostaining consisted of replacing each of the primary
antibodies with equivalent concentrations of an irrelevant mu-
rifle monoclonal or rabbit polyclonal antibody.
In situ hybridization
Osteopontin mRNA transcripts were detected in formalin-
fixed tissues from control rats and angiotensin II infused rats by
in Situ hybridization with osteopontin cRNA probes generated
from the rat smooth muscle osteopontin cDNA, 2B7 [12]. Both
sense and antisense 35S-labeled eRNA probes were prepared as
previously described [13]. Hybridizations were performed over-
night at 55°C using 300,000 cpm/mI cRNA probe [13].
Northern and Western blot analyses
Kidneys were excised from group 2 control and angiotensin II
treated rats and dissected into cortex and medulla. Portions of
these tissues from each animal were quick frozen in liquid
nitrogen and ground into a fine powder under liquid nitrogen.
One sample of tissue powder was processed for RNA prepara-
tion by the method of Chomczynski and Sacchi [14]. Northern
blot analysis was performed as previously described using 2B7
[12], and an oligomer targeted to rat 28S nibosomal RNA
obtained as a gift from Dr. Tom Barrett at the University of
Washington. Autoradiographic analysis was carried out using a
Scanjet lip (Hewlett-Packard) scanner/densitometer and Image-
Quant software (Molecular Dynamics). Cortical and medullary
protein extracts were obtained from a second portion by
dissolving the frozen powder in Laemmli buffer [15] containing
the proteinase inhibitors PMSF (40 mg/mi), bestatin (4 jsg/ml),
pepstatin (0.7 g/ml), EDTA-Na2 (0.37 pg/mI), aprotimn (2
g/ml), and leupeptin (0.5 pg/mI). Samples were forced through
an 18 g needle and boiled for five minutes, centrifuged for five
minutes at 10,000 x g, and supernatants containing osteopontin
were recovered. Protein was quantitated by the microBCA
protein assay (Biorad). Polyacrylamide gel electrophoresis was
performed according to the Laemmli procedure [15]. Proteins
were transferred to nitrocellulose filters using a biorad electro-
blot apparatus. Western blots were performed using MPIIIB1O
(1) as the primary antibody and alkaline phosphatase-linked
secondary antibody. Purified osteopontin was prepared from
12-day-old rat aortic smooth muscle cell culture supernatants
using DEAE-sepharose chromatography followed by barium
citrate precipitation as described [16].
Results
Angiotensin II infusion induces tubular interstitial nephritis in
rat kidney
We previously showed that infusion of Ang II at levels which
produce a moderate level of hypertension in rats induced a
substantial, focal tubulointerstitial cell injury [4]. Figure 1
illustrates the progression of this renal injury. After seven days
of angiotensin II infusion, some focal areas of mildly dilated
tubules were observed, but the majority of the kidney cortex
showed very little morphological differences when compared to
untreated rat kidney (compare Fig. 1 A and C). Notably, an
inflammatory infiltrate consisting predominantly of ED! +
monocyte/macrophages as determined by immunostaining of
adjacent sections (not shown) was evident at this time. In
contrast, after 14 days of Ang IT infusion (Fig, iB), pronounced
tubulointerstitial injury was evident with large areas showing
intratubular cast formation, tubular atrophy, and widening of
the interstitial areas with early fibrosis. At this time, most
pathological changes were visualized in the renal tubular epi-
thelium involving primarily distal tubules and collecting ducts,
but with some injury to proximal tubule cells. Rare glomeruli
showed features of segmental hyalinosis. Injury was often but
not invariably occurring in areas around blood vessels, possibly
accounting for the focal nature of the response. An interstitial
inflammatory cell infiltrate was also evident in areas of struc-
tural damage which by immunostaining with the ED-i antibody
was shown to be primarily monocyte-macrophage rich (not
shown). Renal vascular injury was also marked with some
arterioles displaying hypercellularity and fibrinoid necrosis.
These changes are in striking contrast to the normal morphol-
ogy observed in kidneys infused for 7 or 14 days with vehicle
alone (Fig. 1 C and D, respectively).
Angiotensin 11-infused kidneys express elevated osteopontin
protein
Tissue sections were stained for osteopontin with MPI-
iIBiO(l), a mouse monoclonal antibody to rat osteopontin.
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Fig. 1. Angiotensin II infusion induces focal tubulointerstitial fibrosis. Seven days after Ang II infusion (A) rare areas with mild tubular dilation
and infiltration of mononuclear cells were noted in some biopsies (arrows) however, the majority of the kidney cortex showed the normal
morphology which was also observed in rats infused with vehicle alone for 7 days (C). In contrast, 14 days following angiotensin II infusion (B),
the cortex displayed dramatic morphological changes including tubular dilatation and atrophy, intratubular cast formation, widening of the
interstitial areas, and inflammatory mononuclear cell infiltration. Rats infused with vehicle alone for 14 days showed normal kidney morphology
(D). Sections were stained with Gamori's trichrome with PAS. Original magnification = bOX.
Figure 2A shows MPIIIB 10(1) staining of a seven-day vehicle-
infused rat renal biopsy. Most cortical structures were negative
for osteopontin, although occasional weak staining was ob-
served in some tubular epithelial cells of the distal tubules and
parietal epithelial cells of Bowman's capsules and cortices. In
the medulla (not shown), a much higher level of staining was
observed which was confined to tubular epithelium, collecting
ducts and uroepithelial lining cells, in agreement with previous
findings [17]. An identical staining pattern was observed in rats
infused for 14 days with vehicle alone or in untreated rats, or
when immunostaining was performed with the rabbit polyclonal
antibody to osteopontin (2arC) (data not shown).
In contrast, seven days after angiotensin II infusion, the level
of osteopontin protein was dramatically elevated in tubular
epithelium and Bowman's capsule cells (Fig. 2 B and C). The
most striking effect was seen in the renal cortical regions of
each biopsy which normally expressed very little osteopontin.
At this time, very little morphologic evidence of tubular damage
was observed by PAS stain as shown in Figure 1A. Thus,
elevated osteopontin levels appeared to precede the dramatic
structural changes seen in kidney tubules following chronic
angiotensin II infusion.
After 14 days of infusion, morphological evidence of tubular
damage was pronounced and focal areas of dilated or atrophied
tubules with cast formation were numerous. These were invari-
ably surrounded by tubules which were markedly positive for
osteopontin (Fig. 2 E). In addition, casts were often lined with
cells strongly positive for osteopontin protein. Interestingly, the
staining pattern observed in many positive tubular cells both at
day 7 and day 14 appeared to be polarized such that most of the
signal was detected on the apical side of the cell (Fig. 2 C and
F). The significance of this polarized staining is unclear, but
might indicate directed secretion of osteopontin into the lumen.
The most dramatic changes in osteopontin staining occurred
in the renal cortex which normally expressed very little consti-
tutive osteopontin. No consistent difference in osteopontin
protein levels was observed in medullary regions between
vehicle- and angiotensin-infused rats (not shown). In both Ang
II and vehicle infused rats, osteopontin protein was occasion-
ally seen in the medial layer of renal blood vessels (not shown).
No consistent differences were seen in vascular osteopontin
staining between these groups.
To validate the specificity of MPIIIB 10(1) for rat osteopontin,
Western blot analysis was performed. For this experiment, rats
from either vehicle- or Ang Il-infused groups were sacrificed at
seven days. Kidneys were excised from each animal and
dissected into cortical and medullary regions. Protein extracts
from each were prepared and analyzed by Western blotting. As
shown in Figure 3, vehicle-infused renal medullas contained a
protein of approximately 66 kD which reacted strongly with
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MPIIIB1O(1) and had the same mobility as purified smooth
muscle cell-derived osteopontin. A second protein at —5O kD
was also weakly detected by this antibody. The identity of this
band is unclear, but it might represent a differentially processed
form of osteopontin, since osteopontin has been shown to be
differentially phosphorylated and proteolytically cleaved in
other systems [17]. Rats treated with Ang II for seven days
showed similar sizedantigenic proteins. As seen in the immu-
nohistochemical analysis, kidney cortices showed even more
striking changes in osteopontin protein expression. Very little
immunoreactive 66 kD and 50 kD proteins were observed in
extracts from vehicle infused renal cortex. Equivalent protein
loading was assessed by Coomassie Blue staining of an identi-
cally loaded gel (not shown).
Osteopontin mRNA is synthesized by renal epithelial cells,
and correlates with osteopontin protein levels
Since osteopontin has been reported to circulate in the blood
[18], and has been shown to be expressed by cells of the
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monocytic lineage [191, we used in situ hybridization to deter-
mine whether the increased osteopontin protein levels were due
to increased synthesis of osteopontin by the tubular cells
themselves, or whether accumulation at these sites was due to
exogenous sources (that is, the infiltrating macrophage, or
reabsorption from the tubular fluid). Vehicle infused kidney
showed low intensity signal over tubular epithelial and Bow-
man's capsule cells in the kidney cortex with increased signal
over collecting ducts and epithelial lining cells in medullary
regions using the antisense osteopontin probe (Fig. 4A). Four-
teen days following Ang II infusion, extremely high intensity
signal was observed focally in cortical tubular epithelial cells
(Fig. 4B), and Bowman's capsules. Identical results were
obtained from rats infused for seven days with Ang II (not
shown). Counterstaining of in situ sections with PAS indicated
that the majority of the osteopontin mRNA signal was associ-
ated with distal tubules. At no time was specific signal seen in
cells of the interstitium, suggesting that the tubular epithelial
cells themselves, and not inflammatory cells or interstitial
fibroblasts, synthesize the elevated osteopontin seen at this
time after injury. Specificity of the in situ hybridization was
confirmed by probing similar tissue from Ang Il-infused or
control kidneys with the sense osteopontin cRNA probe in
which no silver grains were observed above background (not
shown).
Northern blot analysis (Fig. 5) showed that all cortex and
medulla samples, regardless of Ang II treatment, contained a
single 1.6 kb transcript hybridizing to 2B7. This is the expected
size for the rat osteopontin mRNA. In general, osteopontin
mRNA levels in untreated rats were higher in rat medulla than
in the cortex. In agreement with in situ results, Ang Il-treated
rat cortices had higher levels (an average of 7-fold) of osteo-
pontin mRNA than untreated cortices.
Colocalization of OPN expressing tubular cells with
monocyte/macrophage infiltrates
Fig. 2. Immunolocalization of osteopontin protein and ED-I + cells in
the kidneys of Ang lI-infused rats. MPIIIBIO(l) was used to localize
osteopontin protein in rat kidneys following infusion with (A) vehicle
alone for 7 days, (B) and (C) Ang II for 7 days, (D) vehicle alone for 14
days, and (E) and (F), Ang II for 14 days. Note the focal osteopontin
staining pattern, as well as the apical distribution of the protein in many
tubules (arrows). (G), (H), and (I), Double immunostaining was per-
formed on kidney biopsies 14 days after Ang II treatment using 2arC
(orange) and ED-i (black) antibodies as described in the Methods. Most
ED-i + cells are found in a peritubular arrangement around osteopon-
tin+ tubules, in some cases contacting osteopontin rich regions (ar-
rows). Original magnification for A, B, D, B = lOOx, 0 = 20x, and C,
F, H, and I = 200x.
Monocyte/macrophage infiltration is an important component
of the tubulointerstitial injury observed in these studies. Utiliz-
ing the ED-i antibody [ii], we observed that the monocyte/
macrophage infiltrates were present early (readily detected at
day 7 of angiotensin infusion; Fig. 2), and were focally distrib-
uted in a pattern strikingly similar to that observed for elevated
osteopontin protein (Fig. 2 B and E). Thus, we utilized a double
staining technique in order to determine whether the osteopon-
tin + and ED-i + cells were found in the same focal region. For
these experiments it was not possible to use the mouse anti-
osteopontin monoclonal antibody, since ED-i is also a mouse
monoclonal antibody of the same isotype, and we therefore
utilized a rabbit polyclonal anti-mouse osteopontin antibody,
2arC. This antibody has been shown to be specific for recom-
binant mouse osteopontin [10], and gave results identical to
MPIIIB iO(i) when used for single immunostaining of biopsy
specimens of vehicle- and angiotensin-infused rat kidneys (not
shown). The results of double immunostaining using 2arC and
ED1 are shown in Figure 2 G, H and I. ED-i + monocytes/
macrophages were found almost exclusively in regions in which
tubules were expressing osteopontin. The ED-i + cells were
found most often in a peritubular distribution (Fig. 2 H and I).
Occasionally, however, ED-i + cells were found between
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Medulla Cortex
Fig. 3. Western blot analyses of osteopontin protein in kidney cortices and medullas. Rats were either infused with vehicle alone (-Ang II) or
angiotensin II (+Ang II) for 7 or 14 days and protein extracts were prepared from kidney medullas (med) or cortices (cor) and processed for
Western blot analyses using the MPIIIBIO(l) antibody. The results obtained from each of two representative animals is shown in comparison to
results obtained with purified osteopontin (OP). The migration of molecular size markers (mw) is also shown. Arrows indicate the position of
migration of 66 kD osteopontin.
Fig. 4. In situ hybridization for osteopontin mRNA in Ang II infused rat kidneys, Rats were infused for 14 days with vehicle alone (A) or
angiotensin 11(B), and in situ hybridization was performed using a 35S-labeled-2B7 riboprobe. Photomicrographs of the resulting hybridization
signals were obtained at 200x magnification on the same field using bright field illumination, Original magnification = 200x.
osteopontin positive tubular epithelial cells or within the tubular
lumen (Fig. 2 H, arrows). No staining was observed when
normal mouse IgG and normal rabbit IgG were used to replace
the primary antibodies in these double staining experiments
(not shown).
Elevated osteopontin protein precedes EDJ +
monocyte/macrophage accumulation
After four days of Ang II infusion, elevated osteopontin
protein was readily detectable in focal tubules throughout the
kidney cortex, Fig. 6A). At this time, there was no detectable
accumulation of ED-i + cells around the osteopontin + struc-
tures, as shown by staining of an adjacent section with ED1
(Fig. 6B).
Discussion
We have investigated the effect of angiotensin II infusion on
osteopontin expression in the rat kidney using RNA hybridiza-
tion and immunochemical methods. We have shown that osteo-
pontin is constitutively expressed in rat kidney, at high levels in
tubular and uroepithelial cells of the medulla, but at a much
lower level in distal tubules and Bowman's capsules in the
—Ang II +Ang II —Ang II +Ang II OP
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Rat number
B
Rat number
Fig. S. Northern blot analysis of osteopontin mRNA levels in kidney cortices and medullas. Total RNA was extracted from portions of tissue
samples prepared as described in Figure 3, and subjected to Northern blot analysis using the 2B7 osteopontin cDNA probe (OP), followed by the
28S ribosomal RNA oligomer probe (28S) for (A) or photography of the 28S rRNA band visualized by UV shadowing of the Northern membrane
(B). The autoradiograms obtained from these analyses on rat medullas (A) and cortices (B) are shown. Rats 1, 2, and 3 were treated with Ang II
for 7 days while rats 4, 5, and 6 received vehicle alone. Exposure times were 16 hours for OP and 2 hours for 28S. The original autoradiogram
showed faint bands for OP mRNA in (B) lanes 4, 5, and 6, but these did not reproduce well. The graph below the autoradiograms shows the results
represented as the OP/28S ratio in arbitrary units and were obtained by densitometric analysis of the blots as described in the Methods.
Fig. 6. Induction of osteopontin protein precedes ED-1+ cell accumulation. Immunolocalization of osteopontin (A) or ED-1+ monocytes/
macrophages (B) 4 days following Ang II infusion. Sections were counterstained with hemotoxylin. The letter "g" indicates the position of the
same glomerulus in the adjacent sections of panel A and B. Original magnification = bOx.
cortex. These data are in good agreement with previous obser-
vations of normal rat kidney osteopontin distribution [17] and
recent findings in mouse kidney [20]. After 7 or 14 days of Ang
II infusion, however, the level of osteopontin expression in the
kidney cortex was dramatically elevated. The Ang II treatment
protocol used in our study also produced focal, tubulointersti-
tial injury characterized by a monocyte/macrophage rich in-
flammatory infiltrate, tubular atrophy and dilation, cast forma-
tion, and fibrosis. The striking increase in osteopontin protein
and mRNA preceded histological evidence of severe tubular
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damage and was focal in nature, suggesting that elevated
cortical osteopontin may be an early marker for tubular dam-
age, and might also have a role in the tubulointerstitial disease
produced by Ang II. The colocalization of osteopontin+ tu-
bules with ED-l+ inflammatory cells suggests that this role
might be to facilitate monocyte/macrophage accumulation at
sites of renal damage.
Osteopontin is a highly acidic, secreted glycoprotein, also
known as uropontin, eta-i, secreted phosphoprotein I, and
bone sialoprotein I [reviewed in 21]. It was originally isolated as
a matrix molecule in bone [22], but has since been found to be
secreted by many tumor and transformed cells [10, 18] as well
as normal cells of the kidney, immune system, placenta and
decidua, brain, bone marrow, inner ear, and blood vessels [12,
17, 22—24]. Although the exact function of osteopontin is
unknown, clues regarding its role in these various tissues have
been obtained from primary sequence analysis and in vitro
studies. Osteopontin contains two highly acidic domains as well
as phosphorylated amino acid residues which have been pro-
posed to be involved in divalent cation binding [21]. Most
interestingly, osteopontin contains a canonical arginine-glycine-
aspartate (RGD) cell adhesion sequence, and purified osteopon-
tin has been shown to facilitate adhesion of cultured fibroblasts
and osteosarcoma cells [25, 26] and most recently, smooth
muscle cells (unpublished observation).
It is intriguing to speculate that the elevated osteopontin
levels seen in the kidney after Ang II infusion in our experi-
ments might be due to a direct effect of Ang II on cortical
epithelial cells. Ang II binding sites have been measured on
proximal convoluted tubules, pars recta, medullary collecting
tubules and distal tubules [27]. Furthermore, we have found
that Ang II, at a concentration of 10 M was a potent direct
inducer of osteopontin mRNA expression and secretion in
cultured vascular smooth muscle cells [16, 28]. However, we
cannot exclude the possibility that Ang II infusion stimulates
osteopontin expression indirectly, perhaps via some systemic
effect such as, for example, elevated blood pressure. Alterna-
tively, elevated cortical osteopontin levels might be related to
other processes occurring as a consequence of Ang II infusion,
such as tubular cell proliferation or inflammation [4]. Both of
these possibilities must be considered since osteopontin has
recently been shown to be associated with cellular proliferation
in vitro [28], and a number of inflammatory cytokines such as
TGF-p, IL-la, TNF-a, and LIF have been shown to stimulate
osteopontin synthesis in various cell types [29—31].
A possible function for osteopontin in Ang Il-induced renal
disease was suggested by our finding that ED- 1 + monocyte/
macrophage cells were found in a peritubular distribution
almost exclusively around tubular cells expressing high levels
of osteopontin. This observation would be consistent with the
hypothesis that Ang II either directly or indirectly stimulates
osteopontin synthesis in tubular cells, and it in turn stimulates
accumulation of immune cells around responding tubular struc-
tures. Our finding that osteopontin protein expression preceded
monocyte/macrophage accumulation four days following Ang
11-infusion is consistent with this possibility. Thus, it is tempt-
ing to speculate that inappropriate expression of osteopontin by
kidney tubules might be important in directing an inflammatory
response, a step which is thought to be critical for the devel-
opment of tubulointerstitial injury [32].
How might osteopontin achieve this? Several hypotheses
based on the reported properties of osteopontin seem likely, but
are by no means the only possibilities. First, osteopontin might
be chemotactic for monocytes and macrophages in the damaged
kidney. This idea is supported by the recent finding that
subcutaneous injection of osteopontin (termed eta-i in that
study), stimulated a macrophage-rich inflammatory infiltrate in
the mouse, and that mouse peritoneal macrophages contain a
large number of high affinity osteopontin binding sites (10,000/
cell) [8]. Although the receptor responsible for osteopontin
binding was not identified in that report, osteopontin has been
shown to bind to the integrin avf33 [33, 34] which has been
previously identified on the macrophage [35]. Secondly, osteo-
pontin might act to stimulate accumulation of monocyte or
macrophage to selected tubules by acting as a preferred adhe-
sive support, much like the role postulated for fibronectin at
sites of inflammation [36]. Lastly, osteopontin may act to inhibit
monocyte or macrophage chemotaxis, thus allowing accumula-
tion of these cells at the appropriate target areas. Whatever the
mechanism, if osteopontin is an important proinflammatory
agent in tubular disease, we would predict that it would be
elevated in other models of tubular injury where inflammation is
thought to be an important part of the pathogenesis of the
disease. Preliminary experiments in tubulointerstital nephritis
associated with three rat models of glomerulonephritis support
this hypothesis since elevated osteopontin is found in all cases
(unpublished observations).
The observation that osteopontin is constitutively expressed
at low, but detectable levels in the normal kidney cortex and at
higher levels in the renal medulla would appear to counter the
hypothesis that tubules express osteopontin as a chernotactic/
adhesive factor for monocytes. However, it is possible that
osteopontin in normal kidney tubules remains intracellular
and/or is directionally secreted into the urine, and thus unavail-
able for interaction with interstitial cells. This would be consis-
tent with recent observations by Shiraga et al that osteopontin
is present in human urine [37]. These investigators have also
proposed that osteopontin may play a role in regulating miner-
alization in the normal kidney based on the observation that
osteopontin (termed uropontin in that report) inhibited calcium
oxalate crystal growth in vitro. In the tubular injury described
here we have observed some necrosis and it is thus conceivable
that osteopontin could be released extracellularly into the
interstitial space as a result. Alternatively, Ang II might directly
effect the compartmentalization of renal osteopontin. In either
case, osteopontin might become available for interaction with
interstitial cells only in the context of tubular injury.
Chemoattractants derived from renal cells and cell adhesion
molecules are thought to play a critical role in tubulointerstitial
fibrosis by recruiting inflammatory cells to tubular areas, yet
very little is known about the molecule(s) which might mediate
this effect. Rovin et al have begun characterization of a lipid
factor which may be involved in monocyte/macrophage chemo-
taxis that occurs following unilateral ureteral obstruction [38].
In a different approach, Heeger et al [39] have identified the
presence of murine RANTES (muRANTES) in proximal tubu-
lar epithelial cells. MuRANTES is an 8000 D protein member
of a new family of small cytokines (Scy superfamily/intercrines)
which have a variety of proinflammatory or reparative pro-
perties in tissues [40]. Another member of the family,
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HuRANTES, the human homologue of MuRANTES, is a
selective chemoattractant for CD4+ lymphocytes and mono-
cytes [41], and is responsive to the modulating influence of
paracrine factors which have a role in the development of renal
parenchymal injury [39]. In addition, leukocyte adhesion mol-
ecules are most likely involved in leukocyte attachment and
accumulation. The intercellular adhesion molecules (ICAM) 1
and 2, vascular cell adhesion molecule-i (VCAM-i), and endo-
thelial leukocyte adhesion molecule-i (ELAM-1) [reviewed in
42] are primary candidates. ICAM-1 and VCAM-i have been
found to be increased on renovascular endothelium and tubular
epithelium in renal allograft rejection [43—46], and both are
increased in proximal tubules in experimental and human
glomerulonephritis in association with tubulointerstitial infil-
trates [47, 481.
In conclusion, our studies are the first to document the
activation of osteopontin during Ang Il-induced tubulointersti-
tial injury in the rat. Furthermore, the temporal pattern of
expression and co-localization of osteopontin and macrophage
in the kidney cortex suggests a role for osteopontin in facilitat-
ing accumulation of these cells near the cortical tubules. This
hypothesis is strengthened by previously described effects of
osteopontin on monocyte-derived cells of the bone and perito-
neal cavity [8, 21]. Furthermore, these data, together with our
recent finding of elevated levels of osteopontin during rat
arterial neointima formation and in human atherosclerotic
plaques [161 suggests that osteopontin may have a broader role
than previously suspected in disease processes.
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